Immunoglobulin Heavy Chains
"Immunoglobulin Heavy Chains" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.
Descriptor ID |
D007143
|
MeSH Number(s) |
D12.776.124.486.485.705.500 D12.776.124.790.651.705.500 D12.776.377.715.548.705.500
|
Concept/Terms |
Immunoglobulin Heavy Chains- Immunoglobulin Heavy Chains
- Heavy Chains, Immunoglobulin
- Ig Heavy Chains
- Heavy Chains, Ig
- Immunoglobulins, Heavy-Chain
- Immunoglobulins, Heavy Chain
- Heavy-Chain Immunoglobulins
- Heavy Chain Immunoglobulins
- Immunoglobulin Heavy Chain
- Heavy Chain, Immunoglobulin
|
Below are MeSH descriptors whose meaning is more general than "Immunoglobulin Heavy Chains".
Below are MeSH descriptors whose meaning is more specific than "Immunoglobulin Heavy Chains".
This graph shows the total number of publications written about "Immunoglobulin Heavy Chains" by people in this website by year, and whether "Immunoglobulin Heavy Chains" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1995 | 0 | 2 | 2 |
1997 | 0 | 4 | 4 |
1998 | 1 | 0 | 1 |
1999 | 5 | 3 | 8 |
2000 | 0 | 2 | 2 |
2001 | 0 | 2 | 2 |
2002 | 1 | 3 | 4 |
2003 | 2 | 4 | 6 |
2004 | 0 | 2 | 2 |
2005 | 3 | 3 | 6 |
2006 | 5 | 4 | 9 |
2007 | 2 | 1 | 3 |
2008 | 2 | 8 | 10 |
2009 | 2 | 3 | 5 |
2010 | 1 | 2 | 3 |
2011 | 1 | 4 | 5 |
2012 | 2 | 3 | 5 |
2013 | 2 | 6 | 8 |
2014 | 2 | 1 | 3 |
2015 | 2 | 6 | 8 |
2016 | 1 | 5 | 6 |
2017 | 2 | 2 | 4 |
2018 | 2 | 1 | 3 |
2019 | 3 | 0 | 3 |
2020 | 1 | 4 | 5 |
2021 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunoglobulin Heavy Chains" by people in Profiles.
-
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia. 2022 03; 36(3):712-722.
-
Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. Cell Rep. 2021 10 05; 37(1):109771.
-
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.
-
Tatibody, a recombinant antibody with higher internalization potency. Mol Immunol. 2021 07; 135:320-328.
-
Discovery of Marburg virus neutralizing antibodies from virus-na?ve human antibody repertoires using large-scale structural predictions. Proc Natl Acad Sci U S A. 2020 12 08; 117(49):31142-31148.
-
Advances in the assessment of minimal residual disease in mantle cell lymphoma. J Hematol Oncol. 2020 09 24; 13(1):127.
-
Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. Cochrane Database Syst Rev. 2020 07 31; 7:CD012022.
-
Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. J Clin Exp Hematop. 2020 Dec 15; 60(4):130-137.
-
Human-likeness of antibody biologics determined by back-translation and comparison with large antibody variable gene repertoires. MAbs. 2020 Jan-Dec; 12(1):1758291.
-
98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia. Cancer Med. 2020 02; 9(3):999-1007.